It was confirmed that dCas9‐TET1CD‐sgRNA2&5 could inhibit tumour growth in vivo by targeting BRD7 for transcriptional activation, demonstrating good anti‐tumour effects without exhibiting in vivo toxic side effects. Here, BRD7 is linked to neoplasm.